BioLargo's PFAS Treatment Technology Meets EPA's Proposed New Drinking Water Standards - Seite 3
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those
about BioLargo's (the "Company") anticipated revenue and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future
results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of
operations, financial condition, and stock price; the effect of global, national and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers
and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions
and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the
dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and
financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations"
sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or
information, which speak as of their respective dates.
Lesen Sie auch
SOURCE: BioLargo, Inc.
View source version on accesswire.com:
https://www.accesswire.com/744105/BioLargos-PFAS-Treatment-Technology- ...
The Biolargo Stock at the time of publication of the news with a fall of -0,90 % to 0,198USD on Nasdaq OTC stock exchange (15. März 2023, 22:20 Uhr).